NervGen Q2 FY26 net loss widens to C$29.2 million - NGEN News | RalliesNervGen Q2 FY26 net loss widens to C$29.2 million
N
NGEN• Q2 net loss widens as cash balance rises
- NervGen posted a Q2 net loss of C$29.2 million, or C$0.32 per share, versus a C$9.1 million loss a year earlier.
- Cash and cash equivalents climbed to C$86.8 million at June 30, 2026, from C$22.1 million at Dec. 31, 2025.
- R&D expenses rose to C$7.9 million from C$2.7 million, driven by RESTORE start-up costs, manufacturing, and toxicology studies.
- G&A expenses increased to C$4.3 million from C$3.8 million, on higher stock-based compensation and insurance tied to the Nasdaq listing.
- RESTORE Phase 3 screening is expected to start in September 2026, with enrollment completion still targeted for 2H 2027 and topline data in 1H 2028.
•
